Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free …
Share
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $71.87 per share. …
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “neutral” rating …
BNS5d
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use …
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (ALNY) stock rocketed to a seven-month high Monday after a Phase 3 trial from rival Ionis Pharmaceuticals (IONS) derisked a key …
Ionis
The company’s market cap is $4.89 billion. Alnylam Pharmaceuticals, Inc. has a …
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) was a big mover last session, as the company saw its shares jump a little above 16% on the day. The upside was driven by the news that its competing drug candidate, patisiran, is …
Alnylam Pharmaceuticals
ALNY) have crossed above the average analyst 12-month target price of $70.69, changing hands for $72.01/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re …
NASDAQ
* Says public offering of 5.00 million common shares priced at $71.87 per share Source text for Eikon: Further company coverage: Our Standards: The Thomson Reuters Trust Principles Next In Market News
Reuters